Glomerular circulatory dynamics were assessed in 60 adult anesthetized rats, which were either deprived or not deprived of water for 24-48 h. Water-deprived rats (n = 21) were characterized by a depressed level of single nephron glomerular filtration rate (SNGFR) when compared with nonwater-deprived controls (n = 8) (23.2 +/-1.3 vs. 44.8 +/-4.1 nl/min). This was primarily due to decreased glomerular plasma flow rate (71 +/-5 vs. 169 +/-23 nl/min) and glomerular capillary ultrafiltration coefficient (0.028 +/-0.003 vs. 0.087 +/-0.011 nl/[s . mmHg]). Infusion of saralasin to these water-deprived rats resulted in significant increases in plasma flow rate and ultrafiltration coefficient, and decline in arteriolar resistances. Consequently, SNGFR increased by approximately 50% from pre-saralasin levels. When water-deprived saralasin-treated rats were given a specific antagonist to the vascular action of arginine vasopressin (AVP), d(CH2)5Tyr(Me)AVP, a fall in systemic blood pressure occurred, on average from 102 +/-5 to 80 +/-5 mmHg, unaccompanied by dilation of renal arterioles, so that both plasma flow rate (129 +/-8 vs. 85 +/-13 nl/min) and SNGFR (31.0 +/-2.9 vs. 18.2 +/-4.4 nl/min) decreased. This more selective extrarenal constrictor action of AVP was further documented in additional studies in which cardiac output and whole kidney blood flow rate were simultaneously measured. In water-diuretic rats, administration of This more selective extrarenal constrictor action of AVP was further documented in additional studies in which cardiac output and whole kidney blood flow rate were simultaneously measured. In water-diuretic rats, administration of a moderately pressor dose of AVP (4 mU/kg per min) resulted in a significant rise in kidney blood flow rate (from 8.8±1.2 to 9.6±13 ml/min). The higher kidney blood flow rate occurred despite a fall in cardiac output (from 111±7 to 98±9 ml/min), and was associated with a significant increase in the ratio of systemic vascular to renal vascular resistance (on average from 0.083±0.014 to 0.106±0.019). Furthermore, infusion of d(CH2)ATyr(Me)AVP to water-deprived animals (a = 6) to antagonize endogenous AVP resulted in systemic but not renal vasodilation, so that kidney blood flow rate fell (by -30%), as did systemic-to-renal resistance ratio (by -30%). When the Portions of these studies were presented at the annual meeting of the American Federation for Clinical Research, Washington, DC, 1983; at the American Society of Nephrology, Washington, DC, 1983; and were published in abstract form (Clin. Res. 31:431, 1983; Kidney Int. 25:293, 1984.
Introduction
Recent evidence indicates that arginine vasopressin (AVP),' in plasma concentrations within the physiological range, exerts a critically important role in the maintenance of blood pressure and systemic circulatory dynamics (1) (2) (3) (4) . The availability of several forms of synthetic analogues to the vascular action of the hormone (1-7) has allowed experimental demonstration of this role.
In addition to its systemic effect, AVP possesses a direct vasoconstrictor action on the glomerular microcirculation. A non-pressor dose of AVP leads to a profound fall in the glomerular capillary ultrafiltration coefficient (Kf) (8) , presumably by inducing mesangial cell contraction (9) . Moreover, in our recent experiments with two-kidney Goldblatt hypertension, an experimental model characterized by a high circulating level of AVP (10) , a specific AVP antagonist was shown to markedly raise Kf. Of related interest are the observations (11) (12) (13) that the renal vasculature is less sensitive to the constrictor action of exogenous AVP than are some extrarenal vascular beds. The present study aims at defining the role of endogenously released AVP in determining the prevailing levels of renal perfusion and filtration during acute extracellular fluid (ECF) volume depletion. The overall functional effect of AVP on renal circulation under a given set of physiological circumstances is not readily predictable, since renal circulatory dynamics are determined by the balance between intrinsic renal and extrarenal vascular tones, as well as the level of cardiac output (CO). We therefore studied the effects of specific antagonism to the vascular action of AVP, by measuring various renal and systemic circulatory indices in water-deprived animals. To document the uniqueness of AVP action, the results were compared with the vasodilatory influence of angiotensin II (AII) inhibition, as well as that of hydralazine, a drug known to dilate both renal and extrarenal vascular beds ( 14) . It should be noted that, although the sympathetic nervous system and circulating catecholamines likely contribute to the prevailing renal hemodynamics in volume-depleted animals, their role will not be addressed in the present study.
Methods
General. Experiments were performed in nine groups of adult male rats. Munich-Wistar rats were used for the experiments involving micropuncture (groups [1] [2] [3] [4] [5] , and Sprague-Dawley rats in studies without micropuncture (groups 6-9) . Before study, the animals were maintained on standard rat pellet chow. In groups [1] [2] [3] [4] 6 , and 7, acute ECF depletion was induced by withholding drinking water 24-48 h before experiment. Rats in groups 5, 8 , and 9 were allowed free access to water until the time of study.
At the time of study, the animals were anesthetized with Inactin (Byk, Federal Republic of Germany; 100 mg/kg, i.p.), placed on a temperature-regulated table, and subjected to tracheostomy. Indwelling polyethylene catheters were inserted into the left and/or right jugular veins for infusion of various intravenous solutions as specified below. The left femoral artery was also catheterized for periodic blood sampling and estimation of mean arterial pressure (AP). The AP was monitored with an electronic transducer (model p23Db, Statham Instruments Div., Gould, Inc., Oxnard, CA) connected to a directwriting recorder (model 2200, Gould Inc.). In group 6-9 animals, a catheter was inserted into the left ventricle through the left carotid artery for injection of radioactive microspheres. Correct placement of the catheter tip was confirmed by pressure tracing. The left kidney was exposed through a left subcostal incision and gently separated from the adrenal gland and the surrounding perirenal fat. In group 1-5 studies, the kidney was suspended on a Lucite holder, and its surface illuminated with a fiberoptic light source and bathed with isotonic NaCl solution heated to 350-370C. A 0.5-ml bolus intravenous injection of 10% inulin in 0.9% NaCl was given, followed by a continuous infusion at the rate of 0.6 ml/h (groups 1-4) or 1.2 ml/h (group 5).
Since the plasma volume of rats prepared surgically in the above fashion is substantially reduced from the level prevailing in the conscious state (14) , estimated plasma losses were replaced in group 1-9 animals with use of the formula described in detail previously (15) . The amount of iso-oncotic plasma used was -1% of body weight in group 5, 8, and 9 animals, and 0.5-0.7% in group 1-4, 6, and 7 animals.
Micropuncture measurements. In group 1-5 animals, micropuncture measurements were carried out as follows: exactly timed (1-2 min) samples of tubule fluid were collected from surface proximal convolutions of two or three nephrons for determination of flow rate and inulin concentration. These Experimental groups. Animals were divided into nine groups. Groups 1-5 underwent micropuncture studies as described above, groups 1-4 being deprived of water for 24-48 h, while group 5 was allowed free access to water until the time of study. Groups 6-9 had simultaneous measurement of AP, CO, and RBF; again, groups 6 and 7 were water deprived for 24-48 h, while groups 8 and 9 were allowed free access to water until the time of study. Individual protocols are described in detail below, and summarized in Table I Group 3 (six Munich-Wistar rats): In group 3 WD, we first studied the effect of d(CH2)5Tyr(Me)AVP alone, followed by the addition of saralasin in the third study period. In these rats, the first study period was carried out as in group 2. Subsequently, d(CH2)5Tyr(Me)AVP was injected as in the third study period of group 2. 20 min later, micropuncture was repeated during the next 30 min. Immediately after this second study period, infusion of saralasin was begun at a rate identical to group 2. After a 40-min equilibration period, measurements and collections again were performed and completed in 30 min (third study period).
Group 4 (six Munich-Wistar rats): In this group of WD, the effect of a nonspecific vasodilator on renal microcirculatory hemodynamics was compared with the effect of AVP antagonist-induced vasodilation (group 2). In this group of animals, the time course described for group 2 was duplicated, except that hydralazine (0.05 mg i.v.) was substituted for the AVP antagonist, and that measurements and collections before saralasin infusion were omitted.
Group 5 (eight Munich-Wistar rats): In order to identify the specificity of endogenous All action in WD animals, the effect of saralasin on the systemic and renal cortical circulations was examined in eight Munich-Wistar rats allowed free access to tap water until the time of the study. In these rats, the protocol for the first and second study periods of group 2 animals was duplicated.
Group 6 (six Sprague-Dawley rats): In these WD, the effect of AVP antagonism in the presence of renin-angiotensin inhibition was studied. An intravenous infusion of teprotide (6 mg/kg per h), an angiotensin I converting enzyme inhibitor, was started immediately after induction of anesthesia, and continued throughout the duration of the experiment. Measurement of AP, CO, and RBF was begun '90 min after surgical preparation, and completed within 15 min. At the end of this first study period, rats received 2O-,g i.v. bolus injection of d(CH2)5Tyr(Me)AVP. 20 min after injection of the AVP antagonist, measurement of AP, CO, and RBF was repeated (second study period).
Group 7 (seven Sprague-Dawley rats): Seven additional WD were used to examine the effect of prostaglandin inhibition on the AVP antagonist-induced changes in AP, CO, and RBF. In this group, the protocol described for group 6 was duplicated except that, in addition to continuous teprotide infusion, group 7 rats received a 2-mg/kg i.v. injection of indomethacin at the start of surgical preparation.
Group 8 (six Sprague-Dawley rats): In these water-diuretic rats, the effect of a moderately pressor dose of exogenous vasopressin on systemic and renal circulatory dynamics was examined. In order to achieve hyposthenuria and suppress endogenous AVP release, the rats were given a continuous hypotonic fluid infusion. Immediately after restoration of the surgical plasma loss, an intravenous infusion (0.83% dextrose, 0.3% NaCl) was started at a rate of 60 ml/kg per h. We previously found this regimen to effectively maintain urine hypotonicity (osmolality below 170 mosmol/kg or specific gravity below 1.005) without significantly changing the serum level of glucose (8) . Approximately 2 h after surgical preparation, measurements of AP, CO, and RBF were begun and completed within 15 min. At the end of this first study period, a continuous intravenous infusion of AVP (4 mU/ kg per min, Pitressin, Parke, Davis & Co., Detroit, MI) was started. 5 min later, after a steady state was reached for AP, the above-mentioned measurements and collections were again performed within a 15-min interval (second study period).
Group 9 (six Sprague-Dawley rats): Using additional water-diuretic rats, the influence of prostaglandin inhibition on the vasopressininduced changes in AP, CO, and RBF was examined. The protocol described for group 8 was duplicated, except that group 9 animals received indomethacin (2-mg/kg i.v. bolus at the start of surgical preparation, followed by 2 mg/kg per h continuous infusion).
Analytical. The volume of fluid collected from individual proximal tubules was estimated from the length of the fluid column in a constant-bore capillary tube of known internal diameter. The concentration of inulin in tubule fluid was measured, usually in duplicate, by the microfluorescence method of Vurek and Pegram (18) . Inulin concentration in plasma was determined by the macroanthrone method of Fuhr et al. (19) . CE and CA were determined, usually in duplicate, by the fluorometric method of Viets et al. (20) .
Analysis of variance was used to determine statistical significance of differences in groups 1-5. Paired and unpaired t test was used for groups 6-9. Statistical significance was defined as P < 0.05. Significance values are given at the levels of <0.05 and <0.01.
Results
Base-line renal microcirculatory indices, measured in 21 waterdeprived rats (groups 1-3) and 8 nonwater-deprived rats (non-WI) (group 5) are presented in Table II . The body weight of group 1-3 animals averaged 276±6 g before water deprivation, which corresponded to a 12±1% loss of body weight during the deprivation. At the time of study, therefore, there was a significant difference in body weight between WD and non-WD animals. Mean arterial pressure was comparable in the two groups. Mean glomerular capillary hydraulic pressure, PGC, was significantly elevated after water deprivation, while proximal tubule hydraulic pressUre, PT, was unchanged, leading to a significantly higher value for the mean glomerular transcapillary hydraulic pressure difference, AP. Efferent arteriolar hydraulic pressure (PE) was comparable in the two groups. Hemoconcentration after water deprivation was reflected by a significant elevation in plasma protein concentration, CA, and hence systemic plasma oncotic pressure, WrA, as well as an increase in hematocrit. Both SNGFR and QA were decreased to a similar extent (-50%) after water deprivation, leading to near-constancy in SNFF. The marked decrease in SNGFR was, therefore, attributed largely to the marked decrease in QA and a simultaneously observed marked decrease in the ultrafiltration coefficient, Kf, as well as, but to a lesser extent, the increase in systemic plasma oncotic pressure, WA. These changes were partly offset by the increase in AP, the latter tending to prevent an even greater reduction in SNGFR. The decrease in QA, in turn, was attributed largely to a marked increase in RA and RE. The increase in RE was proportionately more marked than RA, thus accounting for the observed increase in PGC.
In the absence of pharmacologic intervention (group 1 rats), all hemodynamic and renal microcirculatory indices remained essentially unchanged with time, as shown in Table III.
Administration of saralasin in the second period to group 2 water-deprived rats led only to a slight decrease in AP, on average by 6 mmHg (Table III) . Saralasin treatment induced profound changes in several renal microcirculatory parameters:
PGC decreased while PT remained unchanged, leading to a fall in AP. CA and 7rA were unaffected by angiotensin II inhibition, while both CE and rE decreased. A dramatic increase in QA was observed; its value doubled after saralasin infusion. SNGFR also increased by 11 nl/min. The relatively greater increase in QA than SNGFR was reflected by a fall in SNFF. It is clear from Table III that the increase in QA was the consequence of a profound fall in both RA and RE. The decrease in RA was proportionately less than the decrease in RE, which accounted for the observed decrease in PGC during saralasin infusion. In addition to the increase in QA, Kf was found to markedly increase. Overall, saralasin treatment tended to partially correct the abnormalities seen during water deprivation by modulating the levels of Kf, RA, and REAfter pretreatment with saralasin, administration of the AVP antagonist d(CH2)5Tyr(Me)AVP to group 2 water-deprived rats led to a substantial reduction in AP, on average by 22 mmHg (Table III) inhibition of All in these water-deprived rats pretreated with the AVP antagonist (Table III, The effects of AVP inhibition were compared with those resulting from administration of a systemically equivasodepressor dose of hydralazine in rats also pretreated with saralasin (group 4, third period). Administration of hydralazine resulted in a substantial decrease in AP, on average by -20 mmHg.
Values for PGC and AP decreased as well, leading to a decrease in SNGFR by -40%. CA decreased slightly, and values for both QA and Kf remained essentially unchanged (Table III and Fig. 1 ). Both RA and RE decreased to a mild but significant extent. This dilation of the afferent and efferent arterioles served to maintain QA in the face of systemic vasodilation, the latter evidenced by the profound fall in AP. Overall, the decline in SNGFR was primarily due to the marked fall in PGC. In contrast to the changes seen in group 2 WD animals, saralasin treatment was essentially without effect in group 5 rats having had free access to water, as shown in Table III .
The effect of AVP inhibition on systemic and whole kidney circulatory dynamics was studied in WD pretreated with an angiotensin-converting enzyme inhibitor, teprotide (group 6) ( Table IV, Fig. 2 ). Injection of d(CH2)5Tyr(Me)AVP induced a significant decrease in AP by -30 mmHg without a significant change in cardiac output, so that calculated SVR significantly decreased. Renal blood flow, on the other hand, decreased significantly, on average by 0.9 ml/min, while RVR remained unchanged. Thus, during AVP antagonism, the renal fraction of cardiac output (RBF/CO ratio), or the ratio of SVR/RVR, significantly decreased, from 0.100±0.013 to 0.074±0.015 (P < 0.05) (Table IV, Fig. 2 ).
The effect of AVP inhibition was also studied in WD with indomethacin in addition to teprotide (group 7) (Table IV,   Table IV Fig. 2 ). In these rats, base-line AP and RBF/CO ratio tended to be lower and CO higher than in nonindomethacin-treated rats; however, the differences in these values did not reach statistical significance. After administration of AVP antagonist, a significant decrease in AP was again observed, on average by -20 mmHg, without a significant change in cardiac output, so that SVR significantly decreased. However, in contrast to the pattern seen in group 6 rats, RVR significantly decreased, so that both RBF and RBF/CO ratio remained unchanged.
The effect of exogenous AVP was studied in water-loaded rats (i.e., suppressed endogenous release of the hormone) (group 8) (Table IV, Fig. 3 ). In these animals, the administration of AVP led to a significant increase in AP, on average by -20 mmHg. Cardiac output significantly decreased in association with an increase in SVR. RBF, on the other hand, increased, on average by 0.8 ml/min, despite an increase in RVR. The increase in RBF was due to a proportionately lesser AVPinduced increase in renal as compared with systemic vascular resistance, since RBF/CO or SVR/RVR ratio increased significantly, on average from 0.083±0.014 to 0.106±0.019 (P < 0.01).
In a separate group of water-diuretic rats, AVP was administered while potential stimulation of prostaglandin release by AVP was blocked by pretreating the animals with indomethacin (group 9) (Table IV, Fig. 3 ). In these animals, base-line hemodynamic parameters were not significantly different from those of group 8 animals (Table IV) . Administration of AVP induced an increase in AP, on average by -20 mmHg, a magnitude similar to that seen in group 8 animals. Both SVR and RVR increased. However, in contrast to group 8 animals, AVP induced a comparable increase in both SVR and RVR in these group 9 indomethacin-pretreated animals, so that RBF/CO or SVR/RVR ratio remained essentially unchanged. In association with a uniform (though statistically insignificant) reduction in CO, RBF significantly fell by 1.0 ml/min. 
Discussion
Filtration rate of superficial nephrons during water deprivation was found to be markedly depressed, almost to half the value of control animals. Contributing to the decrease in SNGFR during water deprivation were low levels of QA (-50% of normal controls) and Kf (-30% of normal controls), as well as 1 g/dl increase in systemic plasma protein concentration (Table  II) . A qualitatively similar pattern was previously reported in chronic forms of ECF volume depletion (21, 22) , with the difference that systemic plasma protein concentration, hence IrA, was normal in the chronically volume-contracted state. On the other hand, the glomerular capillary hydraulic pressure, and hence the transcapillary hydraulic pressure difference, were elevated in water-deprived rats, on average by some 15 mmHg above the control levels. This rise in AlP partially offset the changes in the other three determinants and tended to preserve SNGFR.
The relative contribution of each determinant to the low value of SNGFR in WD animals was evaluated. Theoretical values of SNGFR were computed after substituting, successively, a normal value for each of the four determinants of SNGFR, while using the other three values obtained during water deprivation. These predicted values of SNGFR are given in Table V To examine the functional role of the renin-angiotensin system in the markedly altered glomerular microcirculatory dynamics of acutely ECF-depleted animals, the effect of a specific antagonist of All, saralasin, was studied (group 2). Pharmacological blockade of All action led to modest reductions in both systemic arterial and glomerular capillary hydraulic pressure, on average by 6 and 9 mmHg, respectively. In addition, angiotensin inhibition led to reductions in both afferent and efferent arteriolar resistances. This arteriolar vasodilation was sufficient to cause a significant and marked rise in QA, despite the mild systemic vasodilation. Together with a concurrent rise in the ultrafiltration coefficient, the saralasininduced rise in QA brought about an increase in SNGFR, even in the face of a marked fall in PGc. Qualitatively similar effects were seen with All inhibition in volume-depleted animals pretreated with a vasopressin antagonist (group 3). In contrast, saralasin infusion exerted no discernible influence on these parameters in nonvolume-depleted animals (group 5). Thus, the acute form of ECF depletion is characterized by an enhanced vasoconstrictor action of All on renal arterioles, and presumably glomerular mesangium as well, as indicated by the low level of Kf. Hypoperfusion and hypofiltration of glomeruli under this circumstance can therefore be attributed, to a large extent, to the direct constrictor actions of All on the renal microvasculature. Using saralasin or angiotensin I converting enzyme inhibition, previous investigators demonstrated profound direct renal actions of All in the chronic forms of ECF volume depletion (21) and other conditions characterized by high levels of endogenous All (23) (24) (25) (26) .
Our experiments using a specific AVP antagonist demonstrated that the influence of endogenous AVP on renal hemodynamics is clearly different from the direct renal actions of All mentioned above. In the present micropuncture studies, inhibition of AVP action was carried out under two circumstances, without (group 3) or with (group 2) concomitant inhibition of All. When All action was intact (group 3), administration of a specific AVP antagonist caused mild systemic vasodilation (indicated by a slight fall in AP). However, no change was detected in renal arteriolar resistances, so that QA and SNGFR remained essentially constant. When the AVP antagonist was given to AII-inhibited WD (group 2), renal arteriolar resistance again remained unaffected, but a profound systemic vasodilation occurred, which was evidenced by a dramatic fall in AP. A similar selective influence of AVP inhibition on systemic blood pressure was also demonstrated in our recent study of two-kidney Goldblatt hypertension (23), another condition characterized by a high circulating level of AVP (10) .
In the present experiments, simultaneous assessment of cardiac output and whole kidney blood flow allowed further documentation of this extrarenal specific effect of AVP inhibition. In WD animals (group 6), AVP inhibition indeed decreased only systemic (or extrarenal), but not renal, vascular tone. In keeping with this contention that high circulating level of AVP has a preferential constrictor action on the extrarenal vasculature, Heyndrickx et al. (13) , studying conscious dogs, noted that the increase in renal vascular resistance after infusion of a moderately pressor dose of AVP, was less marked than the increase in the resistance of the mesenteric and iliac vascular beds. Similarly, Liard et al. (12) reported that the infusion of AVP to conscious dogs, achieving a serum level within the physiological range, led to a marked decrease in CO while renal blood flow remained unchanged, which implied an increase in relative renal perfusion. Furthermore, Schmid et al. (1 1) , in their study of anesthetized dogs, noted that a low dose infusion of exogenous AVP led to an increase in the absolute value of renal blood flow rate.
That the selective extrarenal action of endogenously released AVP is crucial for the maintenance of glomerular perfusion and filtration in animals with acute ECF volume depletion is readily appreciable from our additional findings using hydralazine. As depicted in Fig. 1 , when this nonselective vasodilator was given to volume-depleted animals (group 4), the resulting fall in AP, comparable with that after AVP inhibition, was accompanied by a parallel fall in renal arteriolar resistance, so that glomerular plasma flow rate remained constant. In contrast, when AVP antagonist was administered, no change occurred in renal arteriolar resistance, which resulted in a marked fall in QA. The systemic effect of AVP inhibition to reduce QA was so profound that a simultaneous tendency for Kf to slightly increase failed to sustain SNGFR.2 2. In our previous study in two-kidney Goldblatt hypertension (23) , AVP inhibition was shown to raise Kf when (but only when) All was In addition to the renin-angiotensin system and vasopressin, the sympathetic nervous system is known to contribute to maintaining the integrity of systemic circulation. Recently, Paller and Linas (3) have demonstrated in conscious rats that, even when two of these pressor systems are impaired, the level of AP can be sustained as long as the third system remains intact. Of note, however, is the evidence indicating that, under barbiturate anesthesia, the ability of the sympathetic nervous system to adjust AP is grossly compromised (27, 28) . Indeed, the rise in plasma catecholamines regularly occurring during hemorrhage was found to be markedly blunted in pentobarbitalanesthetized dogs (29). Thus, although we did not measure catecholamine levels, the efficiency of the sympathetic nervous system is likely to have been compromised by Inactin, thereby accounting for the pronounced hypotension observed in our studies after antagonism of All and AVP in WD animals. 3 AVP is known to stimulate the release of vasodilatory prostaglandins (31) (32) (33) . Renal tissues, including glomeruli, are particularly rich in enzymes that participate in the biosynthesis of prostaglandins (34) (35) (36) . Oliver et al. (37) have recently shown that, in dogs, direct intrarenal arterial administration of AVP augments the renal release of prostglandin E2. Moreover, when the animals were pretreated with indomethacin, enhanced renal constriction was noted during exogenous AVP administration. Our results in water diuretic animals (groups 8 and 9) confirm their findings: Thus, when a mildly pressor dose of AVP was injected intravenously to rats undergoing water diuresis (group 8), a significant increase in renal blood flow and in RBF/CO ratio was seen. However, when potential AVP-induced prostaglandin release was blocked by the cyclooxygenase inhibitor indomethacin (group 9), RBF decreased and RBF/CO was unchanged. These results suggest that, when the intrarenal vasodilatory action of prostaglandins is eliminated, exogenous AVP is equally vasoconstrictive on renal and extrarenal vascular beds. 4 We postulated that the absence of a renal constrictor action of AVP released endogenously in water deprivation, i.e., under physiological conditions, was similarly a consequence of enhanced release of vasodilatory prostaglandins, induced by AVP, and locally attenuating the direct vasoconstrictor effect of the peptide hormone. Thus, administration of AVP antagonist to WD animals led to systemic hypotension and a marked fall in the renal fraction of cardiac output; pretreatment with indomethacin (group 7) essentially simultaneously inhibited. In the present study, however, such a rise, if any, could not be appreciated, due to achievement of filtration-pressure equilibrium (i.e., AP H HE). This indicates that the Krraising effect of AVP inhibition, even if it occurred, failed to affect SNGFR, due to the profound systemic effect of AVP inhibition, which brought about the fall in QA and AP, and attainment of filtration-pressure equilibrium. 3. It should also be noted that the extent to which the differential effect of AVP on systemic vs. renal vasculature affects the overall RBF, depends on the renal capacity of "pressure" autoregulation, i.e., ability to maintain RBF in the face of changes in AP. When this system is compromised, as occurs in ECF volume depletion (30), the systemic effect of AVP to maintain AP becomes a more crucial determinant for the level of RBF. Based on these results, we propose the mechanism for the renal hemodynamic action of AVP shown in Fig. 4 : AVP may possess direct constrictor actions on both extrarenal and renal vasculatures. However, due to the release of vasodilatory prostaglandins, the effect of which is to counteract the direct constrictive action of AVP, renal vascular resistance remains unchanged. This scheme also provides an attractive hypothesis for the role of endogenously released AVP. Thus, our results in group 6 and 7 rats point to the notion that the vasodilatory action of AVP-induced prostaglandins, by protecting the kidney from the constrictor action of AVP, is critically important in diverting to the kidney a higher fraction of the cardiac output, the latter being profoundly depressed under conditions of extracellular fluid depletion.5
